Income Taxes	9 Months Ended
Mar. 31, 2021
Income Taxes
Income Taxes	Note 17. Income Taxes The Company uses the liability method to account for income taxes. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities as measured by the enacted tax rates which are expected to be in effect when these differences reverse. Deferred tax expense (benefit) is the result of changes in deferred tax assets and liabilities. The federal, state and local income tax benefit for the three months ended March 31, 2021 was $2.5 million compared to $1.7 million for the three months ended March 31, 2020. The effective tax rates for the three months ended March 31, 2021 and 2020 were 26.3% and 9.1%, respectively. The effective tax rate for the three months ended March 31, 2021 was higher compared to the three months ended March 31, 2020 primarily due to the relative impact of excess tax shortfalls related to stock compensation as well as a non-deductible branded prescription drug fee in the three months ended March 31, 2021 as compared to the three months ended March 31, 2020. The federal, state and local income tax benefit for the nine months ended March 31, 2021 was $68.6 million compared to $5.2 million for the nine months ended March 31, 2020. The effective tax rates for the nine months ended March 31, 2021 and 2020 were 27.0% and 18.0%, respectively. The effective tax rate for the nine months ended March 31, 2021 was higher compared to the nine months ended March 31, 2020 primarily due to the impact of the CARES Act, which increased the interest expense deductibility limitation in the current year and also allowed the Company to carry back its taxable loss into a prior fiscal year, where the statutory tax rate was 35 %. The impact of excess tax shortfalls related to stock compensation as well as a non-deductible branded prescription drug fee in the nine months ended March 31, 2020 relative to expected pre-tax loss also contributed to a lower effective tax rate as compared to the nine months ended March 31, 2021. The Company may recognize the tax benefit from an uncertain tax position claimed on a tax return only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. As of March 31, 2021 and June 30, 2020, the Company has total unrecognized tax benefits of $4.6 million and $4.6 million, respectively, of which $4.4 million and $4.5 million would impact the Company’s effective tax rate for each period, if recognized. As a result of the positions taken during the period, the Company has not recorded any material interest and penalties for the period ended March 31, 2021 in the statement of operations and no cumulative interest and penalties have been recorded either in the Company’s statement of financial position as of March 31, 2021 and June 30, 2020. The Company will recognize interest accrued on unrecognized tax benefits in interest expense and any related penalties in operating expenses. The Company files income tax returns in the United States federal jurisdiction and various states. The Company’s federal tax returns for Fiscal Year 2014 and prior generally are no longer subject to review as such years are closed. The Company’s Fiscal Year 2015 through 2017 federal returns are currently under examination by the Internal Revenue Service (“IRS”). In March 2021, the Company was notified that its Fiscal Year 2020 federal return was also selected for examination. The Company has received preliminary assessments from the IRS, which are not considered material to Company’s Consolidated Statements of Operations; however, we cannot reasonably predict the final outcome of the examinations at this time. In October 2018, the Company was notified that the Commonwealth of Pennsylvania will conduct a routine field audit of the Company’s Fiscal 2016 and Fiscal 2017 corporate tax returns. In March 2021, the Company received a preliminary assessment from the Commonwealth of Pennsylvania, which is not considered material to the Company’s Consolidated Statement of Operations.

Income Taxes

9 Months Ended

Mar. 31, 2021

Note 17. Income Taxes

The Company uses the liability method to account for income taxes. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities as measured by the enacted tax rates which are expected to be in effect when these differences reverse. Deferred tax expense (benefit) is the result of changes in deferred tax assets and liabilities.

The federal, state and local income tax benefit for the three months ended March 31, 2021 was $2.5 million compared to $1.7 million for the three months ended March 31, 2020. The effective tax rates for the three months ended March 31, 2021 and 2020 were 26.3% and 9.1%, respectively. The effective tax rate for the three months ended March 31, 2021 was higher compared to the three months ended March 31, 2020 primarily due to the relative impact of excess tax shortfalls related to stock compensation as well as a non-deductible branded prescription drug fee in the three months ended March 31, 2021 as compared to the three months ended March 31, 2020.

The federal, state and local income tax benefit for the nine months ended March 31, 2021 was $68.6 million compared to $5.2 million for the nine months ended March 31, 2020. The effective tax rates for the nine months ended March 31, 2021 and 2020 were 27.0% and 18.0%, respectively. The effective tax rate for the nine months ended March 31, 2021 was higher compared to the nine months ended March 31, 2020 primarily due to the impact of the CARES Act, which increased the interest expense deductibility limitation in the current year and also allowed the Company to carry back its taxable loss into a prior fiscal year, where the statutory tax rate was 35 %. The impact of excess tax shortfalls related to stock compensation as well as a non-deductible branded prescription drug fee in the nine months ended March 31, 2020 relative to expected pre-tax loss also contributed to a lower effective tax rate as compared to the nine months ended March 31, 2021.

The Company may recognize the tax benefit from an uncertain tax position claimed on a tax return only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement.

As of March 31, 2021 and June 30, 2020, the Company has total unrecognized tax benefits of $4.6 million and $4.6 million, respectively, of which $4.4 million and $4.5 million would impact the Company’s effective tax rate for each period, if recognized. As a result of the positions taken during the period, the Company has not recorded any material interest and penalties for the period ended March 31, 2021 in the statement of operations and no cumulative interest and penalties have been recorded either in the Company’s statement of financial position as of March 31, 2021 and June 30, 2020. The Company will recognize interest accrued on unrecognized tax benefits in interest expense and any related penalties in operating expenses.

The Company files income tax returns in the United States federal jurisdiction and various states. The Company’s federal tax returns for Fiscal Year 2014 and prior generally are no longer subject to review as such years are closed. The Company’s Fiscal Year 2015 through 2017 federal returns are currently under examination by the Internal Revenue Service (“IRS”). In March 2021, the Company was notified that its Fiscal Year 2020 federal return was also selected for examination. The Company has received preliminary assessments from the IRS, which are not considered material to Company’s Consolidated Statements of Operations; however, we cannot reasonably predict the final outcome of the examinations at this time. In October 2018, the Company was notified that the Commonwealth of Pennsylvania will conduct a routine field audit of the Company’s Fiscal 2016 and Fiscal 2017 corporate tax returns. In March 2021, the Company received a preliminary assessment from the Commonwealth of Pennsylvania, which is not considered material to the Company’s Consolidated Statement of Operations.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References + Details